News

miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

Friday, March 31, 2017

BOULDER, CO – March 31, 2017 – miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery
and development of microRNA-targeted therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan-drug designation
to miRagen’s product candidate, MRG-106, for the treatment of mycosis fungoides. Mycosis fungoides is the most common form of a type of blood cancer
called cutaneous T-cell lymphoma (“CTCL”). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and
in other parts of the body.

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

Wednesday, March 22, 2017

BOULDER, Colo., March 22, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today the results of a study demonstrating that the use of the
VeriStrat® test for patients with non-small cell lung cancer (NSCLC) directly impacts physician treatment decisions in real-world clinical
practice. In the study, use of the VeriStrat test resulted in an 89% decrease in ineffective treatments for patients who tested VeriStrat-Poor.
A “decision impact” study demonstrates that a test changes the way patients are treated after test results are known. The decision impact study on
VeriStrat was published in Current Medical Research and Opinion.

Flagship Bioscience: Is PD-L1 Harmonization on the Horizon?

Wednesday, March 22, 2017

Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential
to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not
only calibrate results across multiple assays, but can optimize cutoff points for patient selection. “The potential to more accurately predict which
patients will respond to therapy should allow diagnostics using cTA™ to command a better price, and reimbursement, than existing companion diagnostics
that require manual assessment by a pathologist.”

InDevR Launches Next-Generation Software for the Cypher One™ System

Tuesday, March 21, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to
improving biopharmaceutical and vaccine manufacturing, today announced the global launch of the next-generation Cypher One™ 3.1 software to further
enhance the functionality of the Cypher One™
automated hemagglutination (HA) and hemagglutination inhibition (HAI) interpretation instrument.